Non-Hodgkin's Lymphoma: Current Strategies, Ongoing Challenges, and Future Treatments in Follicular Lymphoma

Faculty : Steven Horwitz, MD. Associate Attending
Memorial Sloan Kettering Cancer Center, New York, NY
Last Modified: May 3, 2013

Share article


Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year. Upon completion of this activity, participants will be able to: 1)Review recent revisions to NHL treatment guidelines, including updated therapy algorithms, 2) Review the complications associated with treating patients with NHL, and 3) Review the most current data about new therapies, treatment strategies, and combination regimens for NHL.

Continue to Activity


News
Studies outline new options for the standard treatment of various lymphoma types

Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American So



OncoLink Treatment Binder

Select the side effects and forms for your patient's treatment binder

Learn More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.


OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More